Lipicard's KeraKlear(R)- Clear Solution for Dry Eyes.HYDERABAD, India -- Lipicard's KeraKlear 0.05% is another high therapeutic index drug developed through its novel platform technology. Lipicard has developed a large number of high therapeutic index drugs in many therapeutic areas including cardiology, NSAID NSAID: see nonsteroidal anti-inflammatory drug. , immunosuppressant immunosuppressant /im·mu·no·sup·pres·sant/ (-sah-pres´ant) an agent capable of suppressing immune responses. im·mu·no·sup·pres·sant n. An agent that suppresses the body's immune response. etc., using a novel platform technology. Lipicard's KeraKlear 0.05% is a novel NCE NCE Networks of Centres of Excellence NCE New Chemical Entity (pharmaceutical research) NCE Normal Curve Equivalent NCE New Civil Engineer (UK Journal) NCE Non-Commercial Educational NCE New Century Energies with a high level of solubility (60 times more soluble in water than Cyclosporine cyclosporine /cy·clo·spor·ine/ (-spor´en) a cyclic peptide from an extract of soil fungi that selectively inhibits T cell function; used as an immunosuppressant to prevent rejection in organ transplant recipients and to treat severe ), and much lower toxicity (4.5 times less toxic than Cyclosporine). Even at higher concentration of 0.2% w/v, KeraKlear was found to be a clear solution, compared to emulsified Cyclosporine 0.05% ocular drops - the current prescription drug for dry eyes. KeraKlear's clear solution was also stable for over 18 months as indicated in the stability tests. KeraKlear 0.05% has multiple advantages over Cyclosporine 0.05% emulsified solution 1. Higher efficacy than Cyclosporine measured through prophylactic study in rat model with induced ulcerative colitis 2. Better safety profile than Cyclosporine - Therapeutic index of 4.5 demonstrated by mean Disease Activity Index (DAI) in rat model 3. Clear solution - non irritating compared to emulsified Cyclosporine 0.05% ocular drops 4. Clear solution is stable as indicated in stability tests over 18 months 5. Patent protection for KeraKlear 0.05% whereas Cyclosporine 0.05% ocular drops is vulnerable to immediate generic competition According to Sambaru Prasad, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Lipicard Technologies Ltd., KeraKlear 0.05% is clearly superior with high therapeutic index on account of better efficacy, lower toxicity, non-irritating clear ocular solution as well as affording highest patent protection due its novel New Chemical Entity status. About Lipicard Technologies: Lipicard Technologies Limited develops innovative and novel High Therapeutic Index Drugs for Lipid management, cardio protection in collaboration with Life Enhancing Technologies LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control . USA. KeraKlear([R]) is the first safe Ocular Clear solution being developed for dry eyes. PLATROL([R]), the first safe antiplatelet drug, RAVIPROFEN([R]), the first stereo-specific non-toxic NSAID are some of the other high therapeutic drugs under development using a novel platform technology. Next in line are the integrated Lipid management drug for increasing HDL (Hardware Description Language) A language used to describe the functions of an electronic circuit for documentation, simulation or logic synthesis (or all three). Although many proprietary HDLs have been developed, Verilog and VHDL are the major standards. and lowering LDL LDL - ["LDL: A Logic-Based Data-Language", S. Tsur et al, Proc VLDB 1986, Kyoto Japan, Aug 1986, pp.33-41]. . PLATROL([R]), RAVIPROFEN([R]) and KeraKlear([R]) are registered trademarks of Life Enhancing Technologies. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion